Levitra

EBIT of Bayer HealthCare before special items climbed by 26.9 percent to EUR 1,319 million (2004: EUR 1,039 million), with underlying earnings growth strongest in the Pharmaceuticals, Biological Products and Consumer Care divisions.

The underlying EBITDA margin rose to 18.9 percent, which means HealthCare has already exceeded the margin of more than 17 percent targeted for 2006.

In a difficult market environment, sales of Bayer CropScience in 2005 were slightly lower at EUR 5,896 million (2004: EUR 5,946 million).

This was due in particular to lower sales of insecticides and fungicides, which were held back by the exceptionally long droughts in Brazil, southern Europe and Australia.

Nonetheless, underlying EBIT of Bayer CropScience rose by 31.2 percent to EUR 685 million (2004: EUR 522 million), mainly because of the absence of goodwill amortization.

Without this effect, underlying EBIT rose by 6 percent.

The underlying EBITDA margin rose to 21.6 percent.

Against the background of adverse market development, especially in Brazil, Bayer CropScience will not yet be able to achieve its target EBITDA margin of 25 percent for 2006, Wenning said.

Further restructuring will be carried out to improve the subgroup’s profitability.

Bayer MaterialScience achieved by far the highest growth rates for both...

Read more...